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Introduction
Pre-labor rupture of membranes (PROM) occurs in
10% of all pregnancies, about 80% of which are term
pregnancies [1]. Active induction of labor soon after
PROM reduces the risks of maternal and fetal sepsis
[2] compared with conservative management, and 
is associated with a shorter interval from PROM to 
significant uterine contractions and delivery [3].
Misoprostol is a prostaglandin E1 analogue which
is rapidly absorbed after oral administration. Its utero-
tonic and cervical-ripening properties have become
increasingly well-known, and a wealth of information
has emerged from studies investigating its potential
use in obstetrics and gynecology [4]. Misoprostol has
been the drug of choice for induction of labor in devel-
oping countries for almost a decade, because it is cheap,
stable at room temperatures, does not require refriger-
ation prior to use, is easy to prepare and because the
route of administration is convenient [5,6]. These fea-
tures make it ideal for use in developing countries. In
most trials, prostaglandins have been administered
vaginally, which results in a longer half-life than oral
administration. However, low oral dosing may have 
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SUMMARY
Objective: To compare the safety and efficacy of conservative management of pre-labor rupture of membranes
(PROM) at term in patients with an unfavorable cervix, with active treatment using oral misoprostol.
Materials and Methods: This quasi-experimental study was conducted between June 1, 2004 and November
30, 2004 at Bahawal Victoria Hospital, Bahawalpur, Pakistan. Eighty-four multigravid women (parity, < 5) at
≥ 37 weeks’ gestation and with unfavorable cervices were divided equally between group S (study) and group C
(conservative). Group S was given 50 µg of oral misoprostol every 4 hours for a maximum of four doses, while
group C was managed conservatively. The intervals between PROM and significant uterine contractions and
delivery, the mode of delivery, and maternal and fetal/neonatal complications were the main outcome measures.
Results: The intervals between PROM and the onset of uterine contractions and delivery were lower in group S
than group C (9.6 vs. 14.8 hours; p <0.001) and (11.6 vs. 17 hours; p <0.001), respectively. Fewer women delivered
abdominally within 24 hours of PROM in group S than in group C (5% vs. 24%; p <0.05). Induction failure in group
S was less than conservative management failure in group C (10% vs. 60%; p < 0.001). The maternal complication
rate was less in group S than in group C (7% vs. 14%; p >0.05), but the fetal/neonatal complication rate was similar
in both groups (5%).
Conclusion: Oral misoprostol (50µg) is safe and effective for cervical ripening and labor induction in patients with
PROM and an unfavorable cervix. [Taiwan J Obstet Gynecol 2008;47(2):192–196]
Key Words: induction, labor, misoprostol, PROM
*Correspondence to: Dr Mian Usman Farooq, Health
Research Centre, Al-Noor Specialist Hospital,
P.O. Box 6251, Holy Makkah, Saudi Arabia.
E-mail: drus76@yahoo.com
Accepted: January 23, 2008
Taiwan J Obstet Gynecol • June 2008 • Vol 47 • No 2 193
Management of PROM Patients with Unfavorable Cervices
an advantage in induction of labor because of the re-
duced risks of uterine hyperstimulation and tachysystole
[7,8].
The advantage of oral misoprostol, with reference
to PROM, is in the avoidance of repeated vaginal exam-
inations and the subsequently reduced risk of sepsis for
both mother and baby [9]. The recommended dose of
oral misoprostol for labor induction varies from 50µg to
100 µg every 4 hours. A meta-analysis of the Cochrane
library suggested that ≥ 100 µg oral misoprostol for
labor induction, although effective, may prove to be
too high, particularly in parous women with ruptured
membranes or a favorable cervix [10]. There are two
management options for PROM at term: treating the
patient conservatively for 24 to 72 hours; or active man-
agement using oxytocin or prostaglandins to acceler-
ate cervical ripening and avoid chorioamnionitis, and
maternal and neonatal morbidity [11].
The objective of this study was to assess the safety
and effectiveness of an oral dose of 50 µg misoprostol
every 4 hours in women with PROM at term and with
an unfavorable cervix.
Materials and Methods
Study setting
Data were collected for 84 pregnant women who pre-
sented to the labor ward of the Obstetrics and Gyne-
cology Unit, Bahawal Victoria Hospital, Bahawalpur,
Pakistan.
Study design
This was a quasi-experimental study (June 1, 2004 to
November 30, 2004).
Inclusion criteria
The participants were aged between 25 and 35 years,
multigravid (parity, ≤ 5), demonstrated PROM (< 4
hours) at term (≥ 37 weeks), were not in labor, had a
single-fetus pregnancy with cephalic presentation, a
normal cardiotocogram, and an adequate pelvis on
clinical pelvimetry.
Exclusion criteria
Exclusion criteria included established labor at the time
of presentation, signs and symptoms suggestive of
chorioamnionitis (maternal fever, tachycardia, uterine
pain/tenderness, purulent vaginal discharge, fetal tachy-
cardia), primigravid status, fetal distress (meconium),
malpresentation, postdate pregnancy, cord prolapse,
inadequate pelvis on clinical pelvimetry, previous uterine
surgery, sensitivity to misoprostol, and other medical
problems (vaginal bleeding in pregnancy, proteinuric
hypertension, intrauterine growth retardation, diabetes
mellitus).
Procedures and interventions
A detailed history was taken and general physical and
abdominal examinations were performed at the time
of enrollment. Uterine contractility, if any, was noted.
A fetal cardiotocography was performed to confirm fetal
well-being. Rupture of membranes was confirmed by
detection of a pool of amniotic fluid on a sterile specu-
lum and using a nitrazine test. Digital vaginal examina-
tion was avoided. After diagnosis of PROM, baseline
investigations, including complete blood examination,
high vaginal swab, complete urine examination, blood
grouping and Rhesus factor determination, were per-
formed. The patients were then randomized to the
active treatment group or the conservative group, after
full informed consent was obtained. Each subject chose
one of two types of cards labeled “S” (study group) or
“C” (conservative group), and they were divided into
two groups according to these cards.
The study group was administered 50 µg of oral
misoprostol, repeated every 4 hours up to a maximum
of four doses if there were no uterine contractions or less
than two mild contractions in 10 minutes. Before every
dose, a fetal cardiotocography was done to confirm
fetal well-being. When uterine activity suggested the
onset of labor, vaginal assessment was performed and
the women were moved to the labor ward. Maternal
pulse, temperature, and blood pressure were moni-
tored at 4-hourly intervals throughout the procedure.
Continuous fetal and maternal monitoring was per-
formed and detailed records of labor were maintained
with a partogram. Failed induction of labor was defined
as vaginal delivery not achieved within 24 hours of 
initiating induction of labor (after the first dose of
misoprostol).
At the time of delivery, a pediatrician was called into
the delivery room to perform an initial assessment of
the baby and resuscitation, if necessary. The indications
for cesarean section were uncontrolled hyperstimulation,
chorioamnionitis, and/or fetal distress. Any complica-
tions during this procedure were recorded and managed
accordingly.
The conservative group was kept under observation
for 24 hours. Continuous maternal and fetal monitoring
was performed. Detailed records of the progress of
labor were maintained with a partogram. Fetal car-
diotocography was performed every 4 hours to confirm
fetal well-being. Failed conservative management of
labor was defined as vaginal delivery not achieved, or
any intervention required (due to obstetric indications)
Taiwan J Obstet Gynecol • June 2008 • Vol 47 • No 2194
A. Ayaz, et al
within 24 hours of presentation to the labor ward.
After failed conservative management, further options
were discussed with the patients and labor induction
was augmented either with oxytocin or prostaglandins.
Patients who refused any intervention after waiting for
24 hours after PROM underwent abdominal delivery on
maternal request. In both groups, prophylactic antibi-
otics were given. The time of PROM, presentation to
the labor ward, first dose of misoprostol, beginning of
significant uterine contractions (three to five contractions
of moderate to severe intensity in 10 minutes) and
delivery were noted.
Main outcome measures
The main outcome measures were the intervals between
PROM and significant uterine contractions and delivery
in both groups, the rates of failed conservative and active
management, cesarean section rate, and maternal and
fetal/neonatal complications.
The hospital board of directors approved the study,
and all participants gave their written informed consent
after they had been made aware of the purpose of the
study.
Analysis was performed using Chi-squared (χ2) tests
to compare nonparametric data. Student’s t test was
applied to the intervals between PROM and significant
uterine contractions and delivery. A p value of less than
0.05 was considered significant.
Results
All subjects were between 25 and 35 years of age. The
mean age in group S was 29 years, while that in group
C was 31 years. In group S, 28 (67%) subjects had sig-
nificant uterine contractions after a single dose of
misoprostol, while seven (16%), four (10%) and three
(7%) had contractions after two, three and four doses,
respectively (p < 0.001).
In group S, almost all patients showed significant
uterine contractions within 24 hours of PROM, com-
pared with 29 (69%) in group C. The mean interval
between PROM and the onset of significant uterine
contractions was 9.6 hours in group S and 14.8 hours
in group C (p < 0.001). Similarly, the mean PROM-to-
delivery interval was 11.6 hours in group S, compared
with 17 hours in group C (p < 0.001; Tables 1 and 2).
In group S, induction failed in four (10%) subjects
while 25 patients in group C (60%) experienced induc-
tion failure (p < 0.001). Regarding the overall mode of
delivery, four (10%) delivered abdominally in group S,
while 20 (48%) in group C had cesarean sections
(0.01 < p < 0.05). In group S, two cesarean sections
were performed within 24 hours of PROM, while 10 in
group C were performed (0.01 < p < 0.05; Table 3).
Only three (7%) females in group S developed com-
plications, i.e. two cases of uterine hyperstimulation and
one of uterine tachysystole, while six (14%) patients in
group C experienced complications, i.e. five cases of
chorioamnionitis and one of nausea and vomiting.
Overall, the fetal/neonatal complication rate in the two
groups was equal (5%; Table 4).
Discussion
Induction of labor is now more widely used than ever
before [12,13]. According to recent studies, this increase
is mainly due to a rise in the number of inductions per-
formed for marginal or elective reasons. The commonest
indications are elective induction and induction for
postdate pregnancies, usually of 40 to 41 weeks [13].
Women may become distressed when labor has not
started by the expected date, and obstetricians come
under pressure from these patients [14]. Suitable eval-
uation of the pregnancy and consultation with these
patients can ensure the selection of those who will
benefit from labor induction, thus reducing the risk to
the fetus of postmaturity without causing fetal distress
during labor.
We used low-dose misoprostol, because a recent
meta-analysis showed that this was as effective as con-
ventional and more expensive agents and did not cause
any increase in complications [10]. The same dose regime
was also used by Cheung et al [15]. A randomized trial
of 80 women with PROM at term showed that oral
misoprostol reduced the need for oxytocin infusion
Table 1. Interval between pre-labor rupture of membranes
and significant uterine contractions*
Interval (hours) Group S Group C
≤ 24 42 (100) 32 (76)
> 24 0 (0) 10 (24)
Total 42 (100) 42 (100)
*Data are presented as n (%).
Table 2. Interval between pre-labor rupture of membranes
and delivery*
Interval (hours) Group S Group C
≤ 24 42 (100) 32 (76)
> 24 0 (0) 10 (24)
Total 42 (100) 42 (100)
*Data are presented as n (%).
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from 51% to 13% and shortened the interval between
PROM and delivery by 8.7 hours, when compared with
placebo [16]. The results of the current study were
comparable with those of Kwon et al [17] in terms of
success rates and low maternal and fetal risks, with a
similar choice of misoprostol dose.
As shown by our study, the use of misoprostol has
advantages over expectant management, i.e. a decreased
interval between PROM and delivery, low risks of mater-
nal and neonatal morbidity, more vaginal deliveries, and
more deliveries within 24 hours of PROM in the study
group. These results are comparable to the studies of
Cheung et al [15], Alfirevic [16], Mahmood et al [18],
Shetty et al [3], Akyol et al [19], Snehamay et al [20],
and Levy et al [21].
Four previously reported trials evaluated the safety
of oral misoprostol. There were no prenatal deaths in
any of these trials. Based on this meta-analysis, and
our reported experience, oral misoprostol is a safe and
effective agent for the stimulation of labor. Uterine rup-
ture, a previously reported complication [22], did not
occur in our study, nor was it reported in other com-
parable trials [9,23–25].
Chorioamnionitis is a potentially serious compli-
cation resulting from expectant treatment because of
the increased interval between PROM and delivery. 
In their study, Gibbs et al [26] found a high rate of
chorioamnionitis, similar to that in our study (12%) in
the conservatively-managed group, while no patient
actively managed with oral misoprostol developed
chorioamnionitis.
When using misoprostol for induction, monitoring
during labor is important to detect uterine hyperstim-
ulation and fetal distress, and therefore allows for early
interventions of these complications and so ensures
good maternal and fetal outcomes.
We conclude that active management of PROM
with an unfavorable cervix using oral misoprostol results
in a shorter interval between membrane rupture and
delivery, and significantly more patients go into labor
and deliver within 24 hours of PROM. Oral misoprostol
at a dose of 50 µg is effective for cervical ripening and
labor induction, with low rates of cesarean sections and
maternal complications.
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